The peripheral blood neutrophil-to-lymphocyte ratio is superior to the lymphocyte-to-monocyte ratio for predicting the long-term survival of triple-negative breast cancer patients

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Jia, Weijuan ^a   Wu, Jiannan ^a   Jia, Haixia ^b   Yang, Yaping ^a   Zhang, Xiaolan ^a   Chen, Kai ^a   Su, Fengxi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLURBIPROFEN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BLOOD CELL RATIO; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LOG RANK TEST; LYMPHOCYTE COUNT; LYMPHOCYTE MONOCYTE RATIO; MAJOR CLINICAL STUDY; MASTECTOMY; MOLECULAR DYNAMICS; MONOCYTE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UNIVARIATE ANALYSIS; BLOOD; BLOOD CELL COUNT; CYTOLOGY; LYMPHOCYTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHIL; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME FACTOR;

BLOOD CELL COUNT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; NEUTROPHILS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84957890577     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143061     Document Type: Article

References (40)

1. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014; 15: E279-289. doi: 10.1016/S1470-2045(13)70567-9 PMID: 24872111
2. DeSantis C, Ma J, Bryan L, Jemal A Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64: 52-62. doi: 10.3322/caac.21203 PMID: 24114568
3. Masood S Prognostic/predictive factors in breast cancer. Clin Lab Med. 2005; 25: 809-825, viii. PMID: 16308094
4. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013; 13: 759-771. doi: 10.1038/nrc3611 PMID: 24154716
5. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ The systemic inflammation- based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 2013; 88: 218-230. doi: 10.1016/j.critrevonc.2013.03.010 PMID: 23602134
6. Huang SH, Waldron JN, Milosevic M, Shen X, Ringash J, Su J, et al. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2014.
7. Li J, Jiang R, Liu WS, Liu Q, Xu M, Feng QS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One. 2013; 8: E83069. doi: 10.1371/Journal.pone.0083069 PMID: 24386144
8. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013; 30: 432. doi: 10.1007/s12032-012-0432-4 PMID: 23283648
9. Kilincalp S, Coban S, Akinci H, Hamamc M, Karaahmet F, Coskun Y, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur J Cancer Prev. 2014.
10. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-tolymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012; 19: 217-224. doi: 10.1245/s10434-011-1814-0 PMID: 21638095
11. Ni XJ, Zhang XL, Ou-Yang QW, Qian GW, Wang L, Chen S, et al. An Elevated Peripheral Blood Lymphocyte- to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy. PLoS One. 2014; 9: E111886. doi: 10.1371/Journal. pone.0111886 PMID: 25372468
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 8418-8423. PMID: 12829800
13. Melichar B Laboratory medicine and medical oncology: The tale of two Cinderellas. Clin Chem Lab Med. 2013; 51: 99-112. doi: 10.1515/cclm-2012-0496 PMID: 22987835
14. Malyguine AM, Strobl SL, Shurin MR Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother. 2012; 61: 239-247. doi: 10.1007/s00262-011-1148-6 PMID: 22080408
15. Donskov F Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013; 23: 200-207. doi: 10.1016/j.semcancer.2013.02.001 PMID: 23403174
16. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model. Br J Cancer. 2005; 93: 273-278. PMID: 16052222
17. Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B, et al. Neutrophil: Lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013; 20 Suppl 3: S650-660. doi: 10.1245/s10434-013-3136-x PMID: 23884751
18. Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, et al. Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study. Breast. 2013; 22: 301-308. doi: 10.1016/j.breast.2012.07.012 PMID: 22863283
19. Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol. 2015.
20. Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: Particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012; 134: 881-888. doi: 10.1007/s10549-012-2094-5 PMID: 22622810
21. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32: 2959-2966. PMID: 25071121
22. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31: 860-867. doi: 10.1200/JCO.2011.41.0902 PMID: 23341518
23. Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, et al. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Arch Gynecol Obstet. 2014; 289: 141-147. doi: 10.1007/s00404-013-2922-9 PMID: 23828443
24. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348: 203-213. PMID: 12529460
25. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960-1964. PMID: 17008531
26. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29: 1949-1955. doi: 10.1200/JCO.2010.30.5037 PMID: 21483002
27. Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther. 2014; 7: 1743-1752. doi: 10.2147/OTT. S69657 PMID: 25328407
28. Noh H, Eomm M, Han A Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease- specific survival in breast cancer patients. J Breast Cancer. 2013; 16: 55-59. doi: 10.4048/jbc. 2013.16.1.55 PMID: 23593082
29. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, et al. Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Bone Marrow Res. 2013; 2013: 658371. doi: 10.1155/2013/658371 PMID: 23710362
30. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 2005; 26: 281-293. PMID: 16254457
31. Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, et al. A Majority of Low (1- 10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors. J Cancer. 2014; 5: 156-165. doi: 10.7150/jca.7668 PMID: 24563670
32. Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013; 20: 87-93. doi: 10.1245/s10434-012-2588-8 PMID: 22875649
33. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012; 30: 729-734. doi: 10.1200/JCO.2011.36.2574 PMID: 22291085
34. Khoshnoud MR, Lofdahl B, Fohlin H, Fornander T, Stal O, Skoog L, et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat. 2011; 126: 421-430. doi: 10.1007/s10549-010-1202-7 PMID: 20957430
35. Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth. 2014; 113 Suppl 1: I82-87. doi: 10.1093/bja/aet464 PMID: 24464611
36. Forget P, Vandenhende J, Berliere M, Machiels J-P, Nussbaum B, Legrand C, et al. Do Intraoperative Analgesics Influence Breast Cancer Recurrence After Mastectomy? A Retrospective Analysis. Anesthesia & Analgesia. 2010; 110: 1630-1635.
37. Hiller JG, Parat M-O, Ben-Eliyahu S The Role of Perioperative Pharmacological Adjuncts in Cancer Outcomes: Beta-Adrenergic Receptor Antagonists, NSAIDs and Anti-fibrinolytics. Current Anesthesiology Reports. 2015; 5: 291-304.
38. Buyukkaya E, Karakas MF, Karakas E, Akcay AB, Tanboga IH, Kurt M, et al. Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost. 2014; 20: 159-163. doi: 10.1177/1076029612459675 PMID: 22992349
39. Trottier MD, Newsted MM, King LE, Fraker PJ Natural glucocorticoids induce expansion of all developmental stages of murine bone marrow granulocytes without inhibiting function. Proc Natl Acad Sci U S A. 2008; 105: 2028-2033. doi: 10.1073/pnas.0712003105 PMID: 18250324
40. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophillymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015; 26: 750-755. doi: 10.1093/annonc/mdu587 PMID: 25538172